Nash and Fibrosis: From Molecular Phenotypes to Precision Therapeutics

Nash and Fibrosis: From Molecular Phenotypes to Precision Therapeutics is organized by Keystone Symposia on Molecular and Cellular Biology and will be held from Mar 03 - 06, 2024 at Fairmont Banff Springs, Banff, Alberta, Canada.,Description:,Fatty liver disease (FLD) comprises a spectrum of conditions in which excess in liver fat coexists with inflammation , fibrosis and increased risk of cancer. The incidence and prevalence of FLD is increasing rapidly, affecting ~one in four people globally, with concurrent increases in liver related morbidity and mortality.,Despite more than a decade of research from Academia and Industry, clinical trials have failed to bring effective treatments for FLD with fibrosis. The complex and variable interactions between environmental and genetic susceptibility and protective factors have played central roles. Assessing severity of disease and response to therapy have been similarly challenging.,This meeting we dive into FLD metabolic, genetic and molecular diversity to identify novel strategies to tackle this disease. We will examine the latest advances in noninvasive measurements to both assess treatment efficacy and identify subpopulations at risk for liver related events and mortality. We will explore novel drug targets deriving from human genetics studies of variants protective against FLD. Ultimately, these advances will pave the way to precision therapeutics to treat NASH, fibrosis and cancer.